New York/London, 23 January 2020 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS), a biotechnology company focusing on the discovery and development of innovative therapeutics for inflammation and oncology indications, announces the Company has today filed a Form F-3 with the Securities Exchange Commission. An F-3 filing is a shelf registration statement for securities which may enable the Company to potentially conduct a future fundraising (but absent any specific terms at the current time).
Contacts:
|
Tiziana Life Sciences plc Gabriele Cerrone, Chairman and founder |
+44 (0)20 7495 2379
|
|
Cairn Financial Advisers LLP (Nominated adviser) Liam Murray / Jo Turner |
+ 44 (0)20 7213 0880
|
|
Shore Capital (Broker) Antonio Bossi / Fiona Conroy |
+44 (0)20 7601 6125
|
Receive news and updates from Tiziana Life Sciences plc by signing up to get email alerts straight to you on https://ir.tizianalifesciences